Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Retained Earnings (2016 - 2026)

Intellia Therapeutics has reported Retained Earnings over the past 12 years, most recently at -$240000.0 for Q1 2026.

  • Quarterly Retained Earnings rose 99.99% to -$240000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$240000.0 through Mar 2026, up 99.99% year-over-year, with the annual reading at $1.0 million for FY2025, 70.58% up from the prior year.
  • Retained Earnings was -$240000.0 for Q1 2026 at Intellia Therapeutics, down from $1.0 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $1.0 million in Q4 2025 and troughed at -$2.5 billion in Q3 2025.
  • The 5-year median for Retained Earnings is -$1.2 billion (2022), against an average of -$1.1 billion.
  • Year-over-year, Retained Earnings plummeted 611267.82% in 2022 and then soared 126.79% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$1.2 billion in 2022, then skyrocketed by 99.81% to -$2.3 million in 2023, then soared by 126.79% to $605000.0 in 2024, then skyrocketed by 70.58% to $1.0 million in 2025, then tumbled by 123.26% to -$240000.0 in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Retained Earnings are -$240000.0 (Q1 2026), $1.0 million (Q4 2025), and -$2.5 billion (Q3 2025).